Telix Spotlights Next-Gen PSMA Therapy in Educational Webinar — Telix Pharmaceuticals Limited

Event summary

Telix to host educational webinar on April 30, 2026 (AEST) / April 29, 2026 (EDT) focusing on PSMA-targeted radionuclide therapy.
Dr. David N. Cade and Professor Louise Emmett will discuss TLX597-Tx (177Lu-DOTA-PSMA), a second-generation small molecule candidate for prostate cancer treatment.
Professor Emmett to present data from the OPTIMAL-PSMA2 trial of TLX597-Tx.
TLX597-Tx has not received marketing authorization in any jurisdiction.

The big picture

Telix’s webinar underscores the growing emphasis on next-generation PSMA therapies as a cornerstone of prostate cancer treatment. The focus on TLX597-Tx aligns with broader industry trends toward targeted radionuclide therapies, which aim to improve patient outcomes while expanding access to advanced treatments. Telix’s differentiated portfolio approach positions it to compete in an evolving oncology market where precision medicine and theranostics are gaining traction.

What we're watching

Clinical Validation: How OPTIMAL-PSMA2 trial data will influence TLX597-Tx’s development trajectory and regulatory pathway.
Market Differentiation: Whether Telix’s multi-product approach can carve out a distinct position in the competitive PSMA therapy landscape.
Regulatory Progress: The pace at which TLX597-Tx advances toward marketing authorization, particularly in select geographies.